Skip to content

Feasibility of Internet Group CBT-I for Gyn Oncology Patients

Feasibility of Internet-Delivered Group Cognitive Behavioral Therapy for Insomnia in Gynecologic Oncology Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06060158
Enrollment
5
Registered
2023-09-29
Start date
2024-02-26
Completion date
2024-12-10
Last updated
2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Brief summary

The goal of this study is to evaluate the feasibility and acceptability of delivering cognitive behavioral therapy for insomnia (CBT-I) to gynecologic cancer patients in an internet-based small-group setting. Secondary objectives: 1. To compare insomnia symptoms before and after intervention. 2. To evaluate any changes in quality of life symptoms while undergoing the intervention. 3. To evaluate the duration of symptoms improvement after the intervention is complete.

Detailed description

This is a pilot feasibility study looking at delivering CBT-I to gynecologic cancer patients. This study will be completed via a novel internet based small group platform. Twelve eligible participants will meet weekly for 6 weeks while undergoing the CBT-I program.

Interventions

BEHAVIORALCognitive Behavioral Therapy for Insomnia

6 sessions

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This is a pilot feasibility study looking at delivering small group therapy online.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. English-speaking women greater than 18 years old who present to UC Davis Comprehensive Cancer Center for treatment or surveillance of gynecologic cancer 2. Must have access to internet 3. Be able to connect via secure web-based platform 4. Be able to complete online questionnaires 5. Moderate or severe insomnia 6. Have access to a mobile device or computer

Exclusion criteria

1. Participants without ability to connect with both audio and visual through secure web-based platform 2. Participant is currently taking sleep medication prescribed by their provider for sleep disturbance or insomnia - Patients taking over the counter medications or supplements are eligible 3. Participants with remote history of insomnia, but not currently having symptoms of insomnia 4. Have other reasons for poor sleep

Design outcomes

Primary

MeasureTime frameDescription
Attendance6 weeksMain feasibility metric, recorded as number of sessions successfully attended. Participants would need to attend at least 4 sessions of the CBT-I sessions. Therefore, attendance among all participants must be 67% or greater to be considered feasible. A session must be attended for at least 50% of the time or will be counted as missed.
Acceptability24 weeksA three-question survey at the end of each session. Question 1 is yes/no, questions 2 and 3 are write in. At the end of the program, a longer acceptability survey will be conducted. If a participant's response to question 1 indicates acceptability for a given session, that session will be deemed 'acceptable'. If 50% or more of participants rated the session as acceptable, then that session will be rated as acceptable.

Secondary

MeasureTime frameDescription
Insomnia symptoms24 weeksMeasured by Insomnia Severity Index (ISI) with scale range of 0 to 27, higher numbers indicating more severe insomnia
Changes in quality of life symptoms24 weeksMeasured by the 7-item Functional Assessment of Cancer Therapy (FACT-G7) Assessment, with likhert scales from 0-4 and higher numbers indicating more severe symptoms
Sleep Quality24 weeksMeasured by the Pittsburgh Sleep Quality Index (PSQI), score of 0-21 points, higher score indicating more severe difficulty sleeping.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026